Showing 4161-4170 of 6036 results for "".
- Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopiahttps://modernod.com/news/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/2482295/Dopavision announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). MyopiaX delivers targeted photobiomodulation to the eye with the aim of managing the progression of myopia among children. The 6-month outcomes of the randomized, controlled tria
- Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMDhttps://modernod.com/news/opthea-completes-enrollment-in-pivotal-phase-3-clinical-program-with-sozinibercept-in-wet-amd/2482294/Opthea announced that it has completed enrollment in both the COAST and ShORe trials constituting its pivotal phase 3 clinical program. This program is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies compared to
- Latinos En Optometry Launches Redesigned Website and New Domain Namehttps://modernod.com/news/latinos-en-optometry-launches-redesigned-website-and-new-domain-name/2482291/Latinos en Optometry, a non-profit association dedicated to gaining a broader representation of Latinos and Spanish-speaking professionals within the optometry and larger eye care professional community, announced the launch of its redesigned website and new domain name,
- Prevent Blindness Offers New Resources for Education and to Raise Awareness for Stargardt Diseasehttps://modernod.com/news/prevent-blindness-offers-new-resources-for-education-and-to-raise-awareness-for-stargardt-disease/2482289/Prevent Blindness has created new educational materials on Stargardt disease. Coinciding with May’s" IRD Genetic Testing Awareness Month," Prevent Blindness now offers a dedicated web page, fact sheets, a new 'Focus on Eye Health Expert Series' episode, and
- FDA Approves First Interchangeable Biosimilars to Eyleahttps://modernod.com/news/fda-approves-first-interchangeable-biosimilars-to-eylea/2482286/The FDA has approved Biocon’s Yesafili (aflibercept-jbvf) and Samsung Bioepis and Biogen’s Opuviz (aflibercept-yszy) as the first interchangeable biosimilars to Eylea (aflibercept). Yesafili and Opuviz are used to treat wet age-related macular degeneratio
- New Research Reveals COVID-19 Virus Could Damage Visionhttps://modernod.com/news/new-research-reveals-covid-19-virus-could-damage-vision/2482285/Researchers at the University of Missouri School of Medicine have discovered the virus that causes COVID-19 can breach the blood-retinal barrier with potential long-term consequences in the eye. Using a humanized ACE2 mice model, research led by Pawan Kumar Singh, PhD, an assi
- Reichert Launches Tono-Vera Tonometer in the UShttps://modernod.com/news/reichert-launches-tono-vera-tonometer-in-the-us/2482283/Reichert Technologies announced the availability of the Tono-Vera Tonometer with ActiView Positioning System in the United States. Tono-Vera is a new handheld tonometer designed to provide quick, automated, and reliable IOP measurements utilizing rebound to
- Haag-Streit Launches 3D Imaging Option for the Imaging Module 910https://modernod.com/news/haag-streit-launches-3d-imaging-option-for-the-imaging-module-910/2482281/Haag-Streit announced the launch of the Imaging Module 910 3D. "To-date, ophthalmologists have been able to document slit lamp images, but only in 2D. The images presented in two dimensions lack depth, which limits the comprehensive visualization of the observed content. By enhanci
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Arcscan's Insight 100 Ophthalmic Ultrasound Imaging System Approved in Chinahttps://modernod.com/news/arcscans-insight-100-ophthalmic-ultrasound-imaging-system-approved-in-china/2482279/ArcScan announced that the ArcScan Insight 100 has received National Medical Products Administration (NMPA) approval in China. The Insight 100 is designed to allow eye surgeons to more accurately determine the appropriate sizing of phakic IOLs for placement behi